Abbott India enterprise value

Share price at each year-end
Tap a line for its trendCurrentlast closeFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
442442561292240
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
Reference items — trailing FY values
6,9296,9296,4095,8495,349
1,8921,8921,6951,4531,206
1,8161,8161,6231,3821,136
1,3191,3191,0121,213893
1,3191,3191,0121,213893
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

ABBOTINDIA₹26,275.00

Abbott India Ltd.

· Pharma & Health
₹ CrorePeersPFIZERGLAXOIPCALABAJANTPHARMANTHEMMEDANTAGLENMARKBIOCON
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current
last close
- Cash, Equiv & ST Investments239.7291.7560.6442.3442.3
Reference Items — Trailing FY Values
Sales5,348.75,848.96,409.26,929.16,929.1
EBITDA1,205.61,453.11,694.61,892.11,892.1
EBIT1,135.71,381.91,622.81,816.11,816.1
Operating Cash Flow893.41,212.81,011.81,319.21,319.2
Free Cash Flow893.41,212.81,011.81,319.21,319.2
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.